NO178265C - Leukemiinhiberende faktor for anvendelse in vitro, fremgangsmåte for å rense denne, anvendelse derav for testing og/eller diagnostisering in vitro samt diagnostisk reagens eller probe - Google Patents

Leukemiinhiberende faktor for anvendelse in vitro, fremgangsmåte for å rense denne, anvendelse derav for testing og/eller diagnostisering in vitro samt diagnostisk reagens eller probe

Info

Publication number
NO178265C
NO178265C NO885339A NO885339A NO178265C NO 178265 C NO178265 C NO 178265C NO 885339 A NO885339 A NO 885339A NO 885339 A NO885339 A NO 885339A NO 178265 C NO178265 C NO 178265C
Authority
NO
Norway
Prior art keywords
vitro
purifying
diagnosis
probe
diagnostic reagent
Prior art date
Application number
NO885339A
Other languages
English (en)
Norwegian (no)
Other versions
NO885339D0 (no
NO178265B (no
NO885339L (no
Inventor
David Paul Gearing
Nicholas Martin Gough
Douglas James Hilton
Julie Ann King
Donald Metcalf
Edouard Collins Nice
Nicos Anthony Nicola
Richard John Simpson
Tracy Ann Willson
Original Assignee
Amrad Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amrad Corp Ltd filed Critical Amrad Corp Ltd
Publication of NO885339D0 publication Critical patent/NO885339D0/no
Publication of NO885339L publication Critical patent/NO885339L/no
Priority to NO950509A priority Critical patent/NO179210C/no
Publication of NO178265B publication Critical patent/NO178265B/no
Publication of NO178265C publication Critical patent/NO178265C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO885339A 1987-04-02 1988-11-30 Leukemiinhiberende faktor for anvendelse in vitro, fremgangsmåte for å rense denne, anvendelse derav for testing og/eller diagnostisering in vitro samt diagnostisk reagens eller probe NO178265C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO950509A NO179210C (no) 1987-04-02 1995-02-10 Fremgangsmåte for fremstilling av et LIF polypeptid, rekombinant DNA molekyl som koder for LIF polypeptidet samt vertscelle for å uttrykke dette

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPI120987 1987-04-02
AUPI331787 1987-07-24
AUPI490387 1987-10-15
AUPI600587 1987-12-21
PCT/AU1988/000093 WO1988007548A1 (en) 1987-04-02 1988-03-31 Leukaemia-inhibitory factor

Publications (4)

Publication Number Publication Date
NO885339D0 NO885339D0 (no) 1988-11-30
NO885339L NO885339L (no) 1989-02-01
NO178265B NO178265B (no) 1995-11-13
NO178265C true NO178265C (no) 1996-02-21

Family

ID=27424196

Family Applications (1)

Application Number Title Priority Date Filing Date
NO885339A NO178265C (no) 1987-04-02 1988-11-30 Leukemiinhiberende faktor for anvendelse in vitro, fremgangsmåte for å rense denne, anvendelse derav for testing og/eller diagnostisering in vitro samt diagnostisk reagens eller probe

Country Status (15)

Country Link
US (5) US5187077A (da)
EP (1) EP0285448B1 (da)
JP (2) JP2682858B2 (da)
KR (1) KR0121324B1 (da)
CA (1) CA1341581C (da)
DE (1) DE3888379T2 (da)
DK (1) DK174970B1 (da)
ES (1) ES2061643T3 (da)
FI (1) FI113372B (da)
HK (1) HK33695A (da)
IL (1) IL85961A (da)
NO (1) NO178265C (da)
PT (1) PT87133B (da)
SG (1) SG11795G (da)
WO (1) WO1988007548A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
AU623922B2 (en) * 1988-08-04 1992-05-28 Amrad Operations Pty. Limited In vitro propagation of embryonic stem cells
US20030032178A1 (en) * 1988-08-04 2003-02-13 Williams Robert Lindsay In vitro propagation of embryonic stem cells
WO1990002183A1 (en) * 1988-08-18 1990-03-08 Genetics Institute, Inc. Production of a novel lymphokine exhibiting differentiation inhibitory activity
US5284756A (en) * 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
CA2009511A1 (en) * 1989-02-08 1990-08-08 Robert D. Leboeuf Antiproliferation factor
JP3040815B2 (ja) * 1989-11-24 2000-05-15 モナッシュ・ユニバーシティ 随伴細胞に及ぼす白血病抑制因子の増殖作用
FI924134L (fi) 1990-03-20 1992-09-16 Amrad Corp Ltd Foerfarande foer reglering av utvecklingen och bevarandet av en neuron
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5595887A (en) * 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
US5599789A (en) * 1991-12-24 1997-02-04 Amrad Corporation Limited Method for the treatment of tumours and sarcomas
US5916871A (en) * 1992-04-27 1999-06-29 Kansas State University Research Foundation Inhibitory factor
CA2139504A1 (en) * 1992-07-01 1994-01-20 Nicos A. Nicola Leukaemia inhibitory factor-binding protein
WO1994018236A1 (en) * 1993-02-03 1994-08-18 Amrad Corporation Limited Receptor-binding determinant from leukaemia inhibitory factor
US6849427B1 (en) * 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
US5849991A (en) 1994-01-27 1998-12-15 Bresatch Limited Mice homozygous for an inactivated α 1,3-galactosyl transferase gene
JPH09508277A (ja) * 1994-01-27 1997-08-26 ブレサゲン リミテッド ヒト異種移植における超急性拒絶の管理のための物質及び方法
US6184370B1 (en) * 1994-02-03 2001-02-06 Amrad Corporation Limited Receptor-binding determinant from leukaemia inhibitory factor
US5824838A (en) * 1996-05-09 1998-10-20 Cedars-Sinai Medical Center Transgenic mouse model for pituitary disorders associated with LIF overexpression and/or GH underexpression, and its use for testing therapeutic drugs for the conditions
AU4229897A (en) * 1996-07-25 1998-02-20 New York University Polypeptide cofactors that mediate alpha-tubulin and beta-tubulin folding
US6156729A (en) 1997-10-15 2000-12-05 California Institute Of Technology Leukemia inhibitory factor for use in modulating inflammation and pain
AUPP053197A0 (en) 1997-11-26 1997-12-18 Amrad Operations Pty. Limited Compositions
EP1094831A4 (en) 1998-07-06 2004-11-03 Us Gov Health & Human Serv COMPOSITIONS AND METHODS FOR IN VITRO FERTILIZATION
US20040234539A1 (en) * 1999-11-03 2004-11-25 Powderject Research Limited Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
KR100865664B1 (ko) * 2000-06-14 2008-10-29 비스타겐 인코포레이티드 간 줄기 세포를 사용하는 독성 타이핑
NZ519752A (en) 2000-10-20 2005-04-29 Amylin Pharmaceuticals Inc Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US7604807B2 (en) * 2000-12-01 2009-10-20 Auburn University Use of pullulan to isolate and preserve biological material
EP1366148A2 (en) * 2001-01-24 2003-12-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Differentiation of stem cells to pancreatic endocrine cells
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells
WO2003027247A2 (en) * 2001-09-24 2003-04-03 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
DE60239420D1 (de) 2001-12-21 2011-04-21 Thrombogenics Nv Zusammensetzungen für die in vitro herleitung und kultur embryonaler stammzellinien mit keimbahnübertragungsfähigkeit und für die kultur adulter stammzellen
GB0220145D0 (en) * 2002-08-30 2002-10-09 Thromb X Nv Novel compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability
WO2004112661A1 (en) * 2003-06-20 2004-12-29 Myers Thomas H Method and apparatus for strengthening the biomechanical properties of implants
FR2870854B1 (fr) * 2004-05-26 2010-12-31 Oreal Utilisation du lif en ingenierie cellulaire et tissulaire
FR2870739B1 (fr) * 2004-05-26 2008-05-16 Oreal Utilisation du lif en cosmetique et en dermatologie
US20050277124A1 (en) * 2004-06-10 2005-12-15 White Steven M Cardiac conduction system cells and uses thereof
US20070292949A1 (en) * 2006-06-20 2007-12-20 Genzyme Corporation Serum-free media and their uses for chondrocyte expansion
WO2011125948A1 (ja) 2010-04-02 2011-10-13 独立行政法人理化学研究所 Ｅｓ細胞の製造方法
KR101434739B1 (ko) * 2012-08-23 2014-09-01 울산대학교 산학협력단 인간 ＰＤＩｂ´ａ´태그를 이용한 생물학적 활성을 가진 인간 ＬＩＦ 재조합 단백질의 대장균 내 발현 및 정제방법
MX384291B (es) 2013-02-20 2025-03-14 Regeneron Pharma Modificación genética de ratas.
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
WO2019169371A1 (en) * 2018-03-02 2019-09-06 University Of Florida Research Foundation, Incorporated Drug stabilized therapeutic transgenes delivered by adeno-associated virus expression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578355A (en) * 1983-01-12 1986-03-25 The United States Of America As Represented By The Department Of Health And Human Services Plasmid cloning vector pAS1
JPS60105621A (ja) * 1983-11-14 1985-06-11 Agency Of Ind Science & Technol 細胞の分化誘導作用を有する生理活性物質およびその製法
US4616079A (en) * 1984-08-24 1986-10-07 Imreg, Inc. Immunoamplifiers and processes for the extraction thereof
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
JPS62223126A (ja) * 1986-03-25 1987-10-01 Sankyo Co Ltd 血液幹細胞成長因子
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
JPS6448197A (en) * 1987-08-19 1989-02-22 Sanden Corp Goods takeoff port unit for vending machine
JPH01148197A (ja) * 1987-12-04 1989-06-09 Green Cross Corp:The 腫瘍細胞障害因子

Also Published As

Publication number Publication date
JP2721123B2 (ja) 1998-03-04
PT87133A (pt) 1988-04-01
JP2682858B2 (ja) 1997-11-26
PT87133B (pt) 1992-07-31
EP0285448B1 (en) 1994-03-16
CA1341581C (en) 2008-09-30
DE3888379D1 (de) 1994-04-21
EP0285448A3 (en) 1990-08-29
WO1988007548A1 (en) 1988-10-06
HK33695A (en) 1995-03-17
NO885339D0 (no) 1988-11-30
ES2061643T3 (es) 1994-12-16
DK174970B1 (da) 2004-04-05
JPH01502985A (ja) 1989-10-12
JPH07138292A (ja) 1995-05-30
NO178265B (no) 1995-11-13
DK483189A (da) 1989-12-04
US5750654A (en) 1998-05-12
KR0121324B1 (ko) 1997-11-28
FI894613A0 (fi) 1989-09-29
FI894613L (fi) 1989-09-29
IL85961A (en) 1997-03-18
EP0285448A2 (en) 1988-10-05
KR890700610A (ko) 1989-04-26
US5443825A (en) 1995-08-22
US6261548B1 (en) 2001-07-17
FI113372B (fi) 2004-04-15
NO885339L (no) 1989-02-01
DE3888379T2 (de) 1994-07-28
US5187077A (en) 1993-02-16
DK483189D0 (da) 1989-10-02
US5427925A (en) 1995-06-27
SG11795G (en) 1995-06-16

Similar Documents

Publication Publication Date Title
NO178265C (no) Leukemiinhiberende faktor for anvendelse in vitro, fremgangsmåte for å rense denne, anvendelse derav for testing og/eller diagnostisering in vitro samt diagnostisk reagens eller probe
EP0353985A3 (en) Nucleic acid probe for detection of neisseria gonorrhoea
DE68917399D1 (de) Testvorrichtung und Verfahren zur Protein-Untersuchung.
BG36592A1 (en) Composition for treatment of diagnosis indicator paper for testing and for semiquantitative determining of concealed blooding and hemoglobin in biological materials
DE3684194D1 (de) Messfuehler und verfahren zum nachweis und zur quantitativen bestimmung von kraft- und drehmomentkomponenten.
IL72499A (en) Kit and method for the detection of bacteria in a biological test sample by nucleic acid hybridization
DE3864467D1 (de) Geraet und verfahren zur messung von deformationen einer probe.
FI910396A7 (fi) Veteen liukenematon reagenssi, nukleiinihappokoetin, testipakkaus sekä diagnostisia ja puhdistusmenetelmiä
EP0277237A4 (en) METHOD AND PROBE FOR SCREENING FOR BACTERIA IN SAMPLES.
FI901916A7 (fi) Diagnostinen testipakkaus, alukekoostumus, ja näiden käyttö nukleiinihappojen replikaatioon tai havaitsemiseen
DE3686042D1 (de) Verfahren und vorrichtung zur bestimmung von spurenbestandteilen durch gleichzeitige messung der photolumineszenz und eines photoakustischen signals.
CA2022942A1 (en) Method of assessing sensitivity of hiv to zidovudine
DE68905313D1 (de) Enzym-immunoassay zur messung des cyclosporin-a-spiegels in vollblut-proben.
DE59914830D1 (de) Verfahren und testbesteck zur beurteilung der oxid messung ihrer antiradikalen aktivität
CA2235316A1 (en) A method for detecting antipolymer antibodies and a diagnostic test kit for use in aiding the diagnosis of silicone related diseases (srd)
ATE23067T1 (de) Verfahren und vorrichtung zur selbstueberpruefung von mikrorechnergesteuerten schaltgeraeten, insbesondere in kraftfahrzeugen.
IL84421A (en) Chromogenic cryptahemispherands and their preparation and use in detecting electrolytes in an aqueous test sample
KR950702308A (ko) 분만예정시기를 결정하는 진단방법과 이목적에 사용되는 키트(diagnostic method for determining the susceptibility to delivery and reagent kit for use therefor)
DE3863708D1 (de) Geraet und verfahren zur messung von deformationen einer probe.
DE68914679D1 (de) Verfahren und messinstrument für drei komponenten.
DE3779334D1 (de) Verfahren und testsatz zur drogenbestimmung.
DE68919107D1 (de) Verfahren und Gerät zur Testsequenzbestimmung für ein Signalmesssystem.
IL83521A (en) Probe for composite analyzer tester
EP0360871A4 (en) Method for measuring biological activity of antithrombin iii and reagents for the measurement
IL84423A0 (en) Chromogenic hemispherands and their use in detecting electrolytes in an aqueous test sample

Legal Events

Date Code Title Description
MK1K Patent expired